Lv2
150 积分 2024-02-27 加入
Rational design of Gi-biased CB1 agonist with reduced side effects
3天前
已完结
The role of hydrophilic linkers in next-generation antibody-drug conjugates
2个月前
已完结
Productive Syntheses of 1-Ethynylcyclopropylamine and 1-Ethynylcyclobutylamine¹
2个月前
已完结
Advances and challenges in immunosuppressive antibody drug conjugates
2个月前
已完结
Discovery of DN1679 as a Potent, Orally Bioavailable, and Highly Selective CDK12/13 Dual Degrader for the Treatment of Triple-Negative Breast Cancer
3个月前
已完结
Insights on Volume of Distribution of Acids
3个月前
已完结
Selective Reduction of Esters to Access Aldehydes Using Fiddler Crab-Type Boranes
3个月前
已完结
CASE HISTORY: TRUQAP® (CAPIVASERTIB) WITH FULVESTRANT FOR THE TREATMENT OF HR-POSITIVE, HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER WITH PIK3CA/AKT1/PTEN-ALTERATIONS
4个月前
已完结
DEVELOPMENT OF E3 LIGANDS TO ENABLE NEXT-GENERATION DEGRADERS
4个月前
已完结
Targeted protein degradation in the transmembrane and extracellular space
4个月前
已完结
皖公网安备34019202002308
